Nghiên cứu Lâm sàng Sau Khi Thuốc Được Chấp Thuận: Cần Gì và Không Cần Gì

CPMP/ICH/135/95. European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Units. Effective January 17, 1997. Japan’s New GC. and other Rules on Clinical Trials. Japanese Technical Requirements for New Drug Registration 1997. Yakuji Nippo, Ltd.; 1997. WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products. Geneva: World Health Organization; Feb 1, 1994. 21 CFR (Code of Federal Regulations) parts 50, 56, 312, 214, National Archives and Records Administration. Revised as of April 1, 1997. Spilker B. Marketing studies. Drug News Perspect 1990;3(6):369–371. Witte PU. Postmarketing observational studies and phase I. trials in Germany. Appl Clin Trials 1993;2(7):54–60. Venulet J. Potential role of postmarketing research. Drug Exptl Clin Res 1987;XIII:673–683. Toscani MR, Resnick G. Postmarketing studies: methods for implementation and potential use of data. Drug Inf J 1992;26:261–265. Bell RL, O’Brian Smith E. Clinical trial in postmarketing surveillance of drugs. Contr Clin Trials 1982;3:61–68. Edlavitch SA. Postmarketing surveillance methodologies. Drug Intel Clin Pharm 1988;22:68–78. Ellenberg SS, Finkelstein DM, Schoenfeld DA. Statistical issues arising in AIDS clinical trials. J Am Stat Assoc 1992;87:562–569. Cocchetto DM, Jones DR. Faster access to drugs for serious or life-threatening illnesses through use of the accelerated approval regulation in the United States. Drug Inf J 1998;32:27–35. Hakkaraien H, Hattab JR, Venulet J. Phase I. research by pharmaceutical companies. Pharmacopsychiat 1984;17:168–176. Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993;329:2029–2032. Kass Wenger N. Why community physicians should encourage their patients to participate in randomized clinical trials. Circulation 1978;58:963–964. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;ii:349–360. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fubrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985;6:556–585. GISSI (Gruppo Italiano per la Studio dela Streptochinasi Nell-Infarcto Miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;ii:397–401. Royal RM. Ethics and statistics in randomized clinical trials (with discussion). Stat Sci 1991;6:52–88. Antman EM, Lau J, Kupelnick B, et al. A comparison of results of meta-analysis of randomized control trials and recommendations of clinical experts. JAMA 1992;268:240–248. Buyse M, Poplavsky JL. Clinical evaluation of virus safety and inhibitor incidence: statistical considerations. Blood Coagul Fibrinol. 1995:6 (Suppl.2):S86–S92. Waldron HA, Cookson RF. Avoiding the pitfalls of sponsored multicentre research in general practice. Br Med J 1993;307:1351–1354. Buyse M. Potential and pitfalls of randomized clinical trials in cancer research. Cancer Surveys 1989;8:91–105. Strom BL, Miettinen OS, Melmon KL. Postmarketing studies of drug efficacy: when must they be randomized? Clin Pharmacol Ther. 1983;34:1–7. Byar DP, Schoenfeld DA, Green SB, et al. Design considerations for AID. trials. N Engl J Med 1990;323:1343–1348. Tognoni G, Alli C, Avanzini F, et al. Randomised clinical trials in general practice: lessons from a failure. Br Med J 1991;303:969–971. Lamas GA, Pfeffer MA, Hamm P, et al. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992;327:241–247. Boissel J. Impact of randomized clinical trials on medical practice. Contr Clin Trials 1989;4:120S–134S. Peto R, Collins R, Gray R. Large-scale randomized evidence: Large, simple trials and overview of trials. J Clin Epidemiol 1995;48:23–40. Buyse M. The case for loose inclusion criteria in clinical trials. Acta Chir Belg 1990;90:129–131. Yusuf S, Held P, Teo KK, Toretsky ER. Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. Stat Med 1990;9:73–86. Stenning S. The “uncertainty Principle” selection of patients for cancer clinical trials. In: Introducing new treatments for cancer. Williams CJ, ed. New York: John Wiley; 1992. Temple R. Government viewpoint of clinical trials of cardiovascular drugs. Med Clinics N Am 1989;73:495–509. Fleming TR. Treatment evaluation in active control studies. Cancer Treat Rep 1987;71:1061–1065. Makuch RW, Pledger G, Hall DG, et al. Active control equivalence studies. In: Statistical Issues in Drug Research and Development. Pearce KE, ed. New York: Marcel Dekker; 1992. ICH Harmonised Tripartite Guideline for Good Clinical Practice. Brookwood Medical Publications; 1996. Brown L. Implementation of ICH GCP. GCP J. 1998:5;11–14. Buyse M. Regulatory vs public health requirements in clinical trials. Drug Inf J 1993;27:977–984. Jefferys DB. Good Clinical Practice: EC expectations, education, self-regulation, or imposition? Drug Inf J. 1992;26:609–613. ISIS-3 (Second internal study of infarct survival) Collaborative group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anitreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770. CPMP Working Party on Pharmacovigilance. Draft guideline for marketing authorization holders on company-sponsored post-marketing safety studies. 111/3176/93, 1993.